Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sergey Shcherbinin

Showing results (61-70 of 74) with videos related to

Pageof 8
Sort By:
Brain : a Journal of Neurology|April 23, 2019
A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementiaMichael J Pontecorvo, Michael D Devous, Ian Kennedy, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 2, 2025
Modified titration of donanemab reduces ARIA risk and maintains amyloid reductionHong Wang, Emel Serap Monkul Nery, Paul Ardayfio, et al.
JAMA|July 17, 2023
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical TrialJohn R Sims, Jennifer A Zimmer, Cynthia D Evans, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 23, 2025
Alzheimer's Imaging ConsortiumEmma M Coomans, Ruben Smith, Daria Pawlik, et al.
Medrxiv : the Preprint Server for Health Sciences|May 18, 2026
Generating synthetic tau-PET scans in Alzheimer's disease from MRI, blood biomarkers and demographics with deep learningLinda Karlsson, Olof Strandberg, Ruben Smith, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 15, 2018
Evaluation of a PET Radioligand to Image Soumen Paul, Mohammad B Haskali, Jeih-San Liow, et al.
JAMA Neurology|November 26, 2019
Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical TrialsAlette M Wessels, Pierre N Tariot, Jennifer A Zimmer, et al.
Alzheimer'S & Dementia (New York, N. Y.)|January 3, 2025
Discovery and clinical translation of ceperognastat, an O-GlcNAcase (OGA) inhibitor, for the treatment of Alzheimer's diseaseWilliam Kielbasa, Paul Goldsmith, Kevin B Donnelly, et al.
Science Translational Medicine|May 15, 2020
PET ligands [<sup>18</sup>F]LSN3316612 and [<sup>11</sup>C]LSN3316612 quantify <i>O</i>-linked-β-<i>N</i>-acetyl-glucosamine hydrolase in the brainShuiyu Lu, Mohammad B Haskali, Kevin M Ruley, et al.
Nature Medicine|March 4, 2020
Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degenerationElisabeth H Thijssen, Renaud La Joie, Amy Wolf, et al.
Pageof 8

Showing results (61-70 of 74) with videos related to

Sort By:
Pageof 8
Brain : a Journal of Neurology|April 23, 2019
A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementiaMichael J Pontecorvo, Michael D Devous, Ian Kennedy, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 2, 2025
Modified titration of donanemab reduces ARIA risk and maintains amyloid reductionHong Wang, Emel Serap Monkul Nery, Paul Ardayfio, et al.
JAMA|July 17, 2023
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical TrialJohn R Sims, Jennifer A Zimmer, Cynthia D Evans, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 23, 2025
Alzheimer's Imaging ConsortiumEmma M Coomans, Ruben Smith, Daria Pawlik, et al.
Medrxiv : the Preprint Server for Health Sciences|May 18, 2026
Generating synthetic tau-PET scans in Alzheimer's disease from MRI, blood biomarkers and demographics with deep learningLinda Karlsson, Olof Strandberg, Ruben Smith, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 15, 2018
Evaluation of a PET Radioligand to Image Soumen Paul, Mohammad B Haskali, Jeih-San Liow, et al.
JAMA Neurology|November 26, 2019
Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical TrialsAlette M Wessels, Pierre N Tariot, Jennifer A Zimmer, et al.
Alzheimer'S & Dementia (New York, N. Y.)|January 3, 2025
Discovery and clinical translation of ceperognastat, an O-GlcNAcase (OGA) inhibitor, for the treatment of Alzheimer's diseaseWilliam Kielbasa, Paul Goldsmith, Kevin B Donnelly, et al.
Science Translational Medicine|May 15, 2020
PET ligands [<sup>18</sup>F]LSN3316612 and [<sup>11</sup>C]LSN3316612 quantify <i>O</i>-linked-β-<i>N</i>-acetyl-glucosamine hydrolase in the brainShuiyu Lu, Mohammad B Haskali, Kevin M Ruley, et al.
Nature Medicine|March 4, 2020
Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degenerationElisabeth H Thijssen, Renaud La Joie, Amy Wolf, et al.
Pageof 8